Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma

The multikinase inhibitor sorafenib has demonstrated an overall survival benefit in phase III hepatocellular carcinoma (HCC) trials and has become the new standard of care for advanced stages of this disease. However, in clinical practice, the vast majority of patients obtain disease stabilization a...

Descripción completa

Detalles Bibliográficos
Autores principales: GERARDI, ASSUNTA MARIA TERESA, STOPPINO, LUCA PIO, LISO, ARCANGELO, MACARINI, LUCA, LANDRISCINA, MATTEO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576208/
https://www.ncbi.nlm.nih.gov/pubmed/23426789
http://dx.doi.org/10.3892/ol.2013.1131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576208/
https://www.ncbi.nlm.nih.gov/pubmed/23426789
http://dx.doi.org/10.3892/ol.2013.1131

Ejemplares similares